CA2398603A1 - Molecules du facteur 23 de croissance de fibroblastes et procedes d'utilisation correspondants - Google Patents

Molecules du facteur 23 de croissance de fibroblastes et procedes d'utilisation correspondants Download PDF

Info

Publication number
CA2398603A1
CA2398603A1 CA002398603A CA2398603A CA2398603A1 CA 2398603 A1 CA2398603 A1 CA 2398603A1 CA 002398603 A CA002398603 A CA 002398603A CA 2398603 A CA2398603 A CA 2398603A CA 2398603 A1 CA2398603 A1 CA 2398603A1
Authority
CA
Canada
Prior art keywords
polypeptide
fgf
leu
gly
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002398603A
Other languages
English (en)
Inventor
Roland Luethy
Robert Yang
Sidney Suggs
Ildiko Sarosi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2398603A1 publication Critical patent/CA2398603A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des polypeptides du facteur 23 de croissance de fibroblastes et des molécules d'acides nucléiques les codant. L'invention concerne aussi des agents liants sélectifs, des vecteurs, des cellules hôtes et des procédés pour produire des polypeptides FGF-23. L'invention concerne aussi des compositions pharmaceutiques et des procédés pour le diagnostic, le traitement, l'amélioration et/ou la prévention de maladies, troubles et états associés aux polypeptides FGF-23.
CA002398603A 2000-02-15 2001-02-15 Molecules du facteur 23 de croissance de fibroblastes et procedes d'utilisation correspondants Abandoned CA2398603A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US18244200P 2000-02-15 2000-02-15
US60/182,442 2000-02-15
US19890300P 2000-04-20 2000-04-20
US60/198,903 2000-04-20
US74858101A 2001-02-15 2001-02-15
US09/784,581 2001-02-15
PCT/US2001/004778 WO2001061007A2 (fr) 2000-02-15 2001-02-15 Molecules du facteur 23 de croissance de fibroblastes et procedes d'utilisation correspondants

Publications (1)

Publication Number Publication Date
CA2398603A1 true CA2398603A1 (fr) 2001-08-23

Family

ID=27391551

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002398603A Abandoned CA2398603A1 (fr) 2000-02-15 2001-02-15 Molecules du facteur 23 de croissance de fibroblastes et procedes d'utilisation correspondants

Country Status (6)

Country Link
EP (1) EP1257645A2 (fr)
JP (1) JP2005508131A (fr)
AU (1) AU3976701A (fr)
CA (1) CA2398603A1 (fr)
MX (1) MXPA02007619A (fr)
WO (1) WO2001061007A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066595A2 (fr) * 2000-03-08 2001-09-13 Chiron Corporation Gene humain fgf-23 et produits d'expression associes
AU2001245535A1 (en) * 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
JP2004504063A (ja) * 2000-07-19 2004-02-12 アドバンスド リサーチ & テクノロジー インスティテュート 新規線維芽細胞増殖因子(fgf23)および使用方法
CN101275136A (zh) * 2000-08-11 2008-10-01 麒麟医药株式会社 调节磷酸代谢,钙代谢,钙化和维生素d代谢的多肽及其编码dna
WO2002088358A2 (fr) * 2001-04-26 2002-11-07 Geneprot, Inc. Compositions associees au facteur de croissance de fibroblastes humain
DE60329070D1 (de) * 2001-12-28 2009-10-15 Kyowa Hakko Kirin Co Ltd Antikörper gegen den fibroblastenwachstumsfaktor 23
US7094551B2 (en) 2002-09-17 2006-08-22 Zahradnik Richard J Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23
US7883705B2 (en) 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
BRPI0911491A2 (pt) * 2008-04-29 2016-01-05 Novartis Ag métodos de monitoramento da modulação de atividade de quinase de receptor de fator de crescimento de fibroblasto e usos dos ditos métodos.
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
EP3798228A1 (fr) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions et procédés pour le traitement de troubles métaboliques et de maladies
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
NZ718962A (en) 2013-10-28 2019-12-20 Ngm Biopharmaceuticals Inc Cancer models and associated methods
RS60593B1 (sr) 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
EP3155005A4 (fr) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Procédés et utilisations pour la modulation de l'homéostasie de l'acide biliaire et le traitement de troubles et maladies de l'acide biliaire
SG11201702757YA (en) 2014-10-23 2017-05-30 Ngm Biopharmaceuticals Inc Pharmaceutical compositions comprising peptide variants and methods of use thereof
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
CA2969307A1 (fr) 2014-12-04 2016-06-09 Novartis Ag Procedes et compositions employant des polypeptides variants de klotho
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド 胆汁酸に関係した障害の治療方法
US11370841B2 (en) 2016-08-26 2022-06-28 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1032668B1 (fr) * 1997-11-25 2008-05-28 Genentech, Inc. Facteur de croissance des fibroblastes 19
WO2000060085A1 (fr) * 1999-04-02 2000-10-12 Millennium Pharmaceuticals, Inc. Facteur de croissance 20 des fibroblastes
JP2004522402A (ja) * 1999-06-02 2004-07-29 ジェネンテック・インコーポレーテッド 同一のものをコードする分泌及び膜貫通ポリペプチドと核酸
EP1246843A1 (fr) * 2000-01-05 2002-10-09 ZymoGenetics, Inc. Nouvel homologue du fgf, zfgf12

Also Published As

Publication number Publication date
WO2001061007A3 (fr) 2002-03-14
WO2001061007A2 (fr) 2001-08-23
AU3976701A (en) 2001-08-27
EP1257645A2 (fr) 2002-11-20
JP2005508131A (ja) 2005-03-31
MXPA02007619A (es) 2002-12-13
WO2001061007A9 (fr) 2002-04-18

Similar Documents

Publication Publication Date Title
US20060160181A1 (en) Fibroblast Growth Factor-23 molecules and uses thereof
US7348162B2 (en) Nucleic acids encoding fibroblast growth factor receptor-like proteins and uses thereof
AU3976701A (en) Fibroblast growth factor-23 molecules and uses thereof
US7531321B2 (en) Fibroblast growth factor-like molecules and uses thereof
AU2001241968A1 (en) Chordin-like-2 molecules and uses thereof
EP1266000A1 (fr) Molecules de type chordine 2 et utilisations de celles-ci
CA2481509A1 (fr) Molecules de tyrosine kinase du recepteur her-2 et utilisations associees
WO2002000723A2 (fr) Molecules de recepteur de lymphopoietine de stroma thymique et utilisations de celles-ci
AU2006200916B2 (en) Secreted Epithelial Colon Stromal-1 Polypeptides, Nucleic Acids Encoding the Same and Uses Thereof
US20140273089A1 (en) Fibroblast Growth Factor Receptor-Like Molecules and Uses Thereof
CA2419491A1 (fr) Molecules du recepteur 8 couple a la protenie g contenant des repetitions riches en leucines, et utilisations associees
US7842784B2 (en) Chordin-like molecules and uses thereof
US20020151695A1 (en) Transforming growth factor-beta-related molecules and uses thereof
EP1947182A1 (fr) Molécules 23 à facteur de croissance de fibroblaste et utilisations associées
JP2006238894A (ja) 線維芽細胞成長因子−23分子およびその使用
AU2006200820A1 (en) Fibroblast Growth Factor-23 Molecules and Uses Thereof
AU2005209710A1 (en) Fibroblast Growth Factor Receptor-Like Molecules and Uses Thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead